Best Genomics Companies in Cambridge, United Kingdom
The 52 best Genomics companies in Cambridge, United Kingdom in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Inivata.
Our analysis of 50 Genomics companies
$7.8b in tracked funding; 84% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Genomics companies in Cambridge
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Inivata Developer of liquid biopsy platform for detecting cancer | $189M | 65 mo ago | 81 | Davina Gale Co-founder | Acquired | 97 patents Liquid biopsy and nucleic‑acid analysis for cancer detection and monitoring. | — |
| 2 | Biomodal Developer of a duet multiomics platform that generates genetic and epigenetic data | $164M | 56 mo ago | 84 | Peter Fromen CEO | Series D | 7 patents Genomic and epigenomic analysis tools for DNA sequencing, methylation, and expression prediction | — |
| 3 | Microbiotica Developer of live bacterial therapeutics and biomarkers for multiple diseases | $83M | 52 mo ago | 42 42 → 55 (+31%) | Gordon Dougan Co-Founder | Series B | 30 patents Engineered therapeutic bacterial formulations for microbiome-based disease treatment | 1 award |
| 4 | Congenica Developer of software for clinical genomic interpretation and variant analysis | $82M | 61 mo ago | 79 | Richard Durbin Co-Founder | Acquired | 32 patents Clinical genomic analysis and interpretation tools for prenatal and rare disease diagnostics | 1 partnership |
| 5 | Sphere Fluidics Developer of Single-cell analysis systems for biologics discovery | $57M | 56 mo ago | 29 | — | Series C | 114 patents Microfluidic droplet generation and manipulation for high-throughput biological assays. | — |
| 6 | KuDos Pharmaceuticals Developer of oncology therapies based on the inhibition of DNA repair | $54M | 81 mo ago | 8,185 | Barrie ward Ex-CEO | Acquired | — | — |
| 7 | Horizon Discovery Developer of cell lines with genetic modification using AAV gene-editing platform | $46M | 94 mo ago | 432 | Alberto Bardelli Co-Founder | Acquired | 46 patents Patents concentrated in chemistry & materials | — |
| 8 | NeoPhore Developer of small molecule therapies to treat cancer | $45M | 29 mo ago | 10 10 → 18 (+80%) | Alberto Bardelli Co-Founder | Series B | 32 patents Patents concentrated in chemistry & materials | — |
| 9 | Eagle Genomics Developer of cloud-based software solutions for genomic analysis | $39M | 34 mo ago | 125 | Anthony Finbow CEO | Series C | — | — |
| 10 | Base4 Microdroplet-based single molecule sequencing technology | $25M | 104 mo ago | 16 | — | Deadpooled | — | — |
| 11 | De Novo Pharmaceuticals Provider of computational drug design software and services | $24M | 300 mo ago | 11 | Philip Dean Co-Founder | Deadpooled | 6 patents Antibacterial enzyme inhibitor therapeutics targeting bacterial metabolic enzymes | — |
| 12 | Eleven AI-based RNA drug development platform for researchers 55Growth top 28%Talent top 28%Funding top 31%AI top 45% All 8 signals ▾Growthtop 28% Talenttop 28% Fundingtop 31% AItop 45% Newsbottom 48% Techbottom 44% Globalbottom 37% Marketbottom 25% Growth: Web rank 50,000,000 → 10,000,000 YoY · Fresh capital in last 24 mo Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 55/100 | $22M | 15 mo ago | 12 12 → 28 (+133%) | Shaul Ilan Co-Founder | Seed | — | 1 launch |
| 13 | 14M Genomics Provider of a technology that utilizes next gen sequencing and proprietary analytics for cancer diagnostics | $20M | 139 mo ago | 20 | — | Deadpooled | — | — |
| 14 | Enhanced Genomics Digital platform focused on decoding the causal biology behind genetic variations to accelerate drug discovery | $19M | 10 mo ago | — | Peter Fraser Co-Founder | Series A | — | — |
| 15 | Population Genetics Developing and out-licensing biochemical tools and approaches for NGS applications | $18M | 176 mo ago | 5 | Sam Eletr Co-Founder & Chairman | Deadpooled | 116 patents Advanced DNA sequencing library prep, normalization, and high‑sensitivity variant detection | — |
| 16 | PredictImmune Developer of tools for diagnosing immune-mediated inflammatory diseases | $18M | 83 mo ago | 15 | — | Series B | — | — |
| 17 | Xap Therapeutics Developer of cell therapies to treat cancer and autoimmune diseases | $17M | 52 mo ago | 12 | Shaun Foy Co-Founder | Seed | — | — |
| 18 | Broken String Biosciences Developer of biopharmaceutical products & cell therapies by using genome sequencing data | $15M | 34 mo ago | 4 | Felix Dobbs Co-Founder & CEO | Series A | 9 patents High-throughput nucleic acid sequencing and DNA double‑strand break detection technologies | 1 job opening |
| 19 | Camena Bioscience Developer of a nucleic acid synthesis technology platform | $10M | 36 mo ago | 4 | Steve Harvey Co-Founder & CEO | Series A | 39 patents Patents concentrated in chemistry & materials | — |
| 20 | Plaquetec Developer of a method to profile the biology of coronary artery 22Talent top 28%Moat top 39%Product top 41%News top 43% All 10 signals ▾Talenttop 28% Moattop 39% Producttop 41% Newstop 43% Patentstop 45% Fundingtop 49% Techbottom 49% Innovationbottom 47% Globalbottom 42% Marketbottom 15% Talent: Analyst team rating 4/5 Moat: Editorial + unicorn rating 3/10 · IP moat: 44 patents rank vs industry peers · Fliar Intelligence Index 22/100 | $8M | 3 mo ago | 2 | — | Series A | 42 patents Vascular catheter mixing sheaths for intravascular biomarker sampling and analysis | — |
| 21 | Avvinity Therapeutics Developer of immunotherapeutics for immuno-oncology diseases | $8M | 124 mo ago | 5 | — | Deadpooled | 15 patents Novel heterocyclic small‑molecule drugs for therapeutic applications | — |
| 22 | Cambridge Cancer Genomics Developer of AI-based precision medicine tools for oncologists | $5M | 91 mo ago | 16 | — | Acqui-Hired | — | — |
| 23 | Repositive Developer of software platform to facilitate data access, data sharing, and data collaborations | $4M | 113 mo ago | 9 | — | Series A | — | — |
| 24 | Nemesis Bioscience Developer of therapeutics to reverse microbial resistance to antibiotics | $3M | 52 mo ago | 8 | Frank Massam Founder & CEO | Seed | 24 patents Nucleic acid delivery vectors and therapeutic formulation technologies for gene‑based medicines. | — |
| 25 | PetaGene Provider of cloud-based software for genetic data storage, transfer and remote access | $3M | 91 mo ago | 11 | Alban Rrustemi Co-Founder | Acquired | 22 patents High‑performance genomic data storage and retrieval systems | — |
| 26 | Cell Guidance Systems Develops and markets reagents for stem cell research. | $2M | 26 mo ago | 17 | — | Series A | — | — |
| 27 | Tailor Bio Developer of targeted therapies for cancers with chromosomal instability | $772K | 48 mo ago | 10 | Geoff Macintyre Founder | Funding Raised | — | — |
| 28 | Gene Advisor Online marketplace for genetic testing | $506K | 121 mo ago | 5 | Jelena Aleksic ex-CEO | Deadpooled | — | — |
| 29 | AgeCurve Provider of direct-to-consumer molecular profiling kits | $169K | 54 mo ago | 1 | Attila Csordas Founder & Director | Seed | 5 patents Computational cellular lineage analysis for biological age estimation | — |
| 30 | Genestack Bioinformatics platform for genomics research and development | $138K | 129 mo ago | 9 | — | Funding Raised | — | — |
| 31 | Cambridge Protein Arrays Developer of DNA microarray to protein microarray(DAPA) platform | $120K | 114 mo ago | 2 | — | Funding Raised | — | — |
| 32 | AptaCam Provider of cloud-based device for molecular diagnostics | $113K | 105 mo ago | 3 | — | Deadpooled | — | — |
Top 12 Genomics companies in Cambridge
#1
Series A · Cambridge, England · founded 2008 · 2 employees$8Mraised▾
Developer of a method to profile the biology of coronary artery. It is building cohorts to endotype the disease for the first time. The approach enables the identification of new disease-specific drug targets. This paves the way for precision medicine for patients with coronary artery disease.
- Apr 2026Series A$5M
- Apr 2024Series A$8M
#2
Series A · Cambridge, England · founded 2020$19Mraised▾
Digital platform focused on decoding the causal biology behind genetic variations to accelerate drug discovery. The company uses proprietary GenLink 3D multi-omics platform analyzes genome folding and links disease-associated variants to target genes across the entire human genome, enabling faster identification of high-confidence therapeutic targets for common diseases like autoimmune conditions.
- Sep 2025Series A$19M
#3
Seed · Cambridge, England · founded 2020 · 12 employees$22Mraised▾
AI-based RNA drug development platform for researchers. The company harnesses the power of combinatorial chemistry and AI to transform RNAi drug development into a programmable process against influenza and SARS-CoV-2.
- Apr 2025Grant (prize money)$3M
- Feb 2025Grant (prize money)$320K
- Aug 2022Seed$18M
- Aug 2022Grant (prize money)$4M
#4
Series B · Cambridge, England · founded 2017 · 10 employees$44.6Mraised▾
Developer of small molecule therapies to treat cancer. The therapies target genetic mechanisms to create neoantigen which stimulates the immune system. The company engages in the inactivation of the DNA mismatch repair (MMR) gene which promotes neoantigen creation and provides immunity against numerous cancers
- Feb 2024Series B$12.2M
- Jan 2023Series B$7.4M
- Mar 2021Series B$21M
- Nov 2017Series A$3.9M
#5
Series C · Cambridge, England · founded 2008 · 125 employees$38.7Mraised▾
Eagle Genomics provides cloud-based software solutions for genomic analysis. The company's products include Eaglecore and EagleEnsembl. Eaglecore is a platform for collaborative information management in R&D. EagleEnsembl is a platform for searching and analyzing genomic data.
- Sep 2023Series C$3.7M
- Oct 2022Series C$20M
- Oct 2020Series B$9M
- Jan 2019Series A$3.5M
#6
Series D · Cambridge, England · founded 2012 · 84 employees$164.1Mraised▾
Developer of a duet multiomics platform that generates genetic and epigenetic data. It offers a duet multi-omics solution +modC which uses next-generation sequencing and a platform to acquire genetic and epigenetic methylation information. It is used for cancer research, Non-invasive prenatal testing, precision medicine, and others.
- Nov 2021Series D$88M
- Jan 2020Grant (prize money)$1.2M
- Apr 2018Series C$37.7M
- Jan 2016Series B$21M
#7
Acquired · Cambridge, England · founded 2014 · 81 employees$188.8Mraised▾
Developer of liquid biopsy platform for detecting cancer. The company's technology allows improving sensitivity and coverage of larger gene panels compared to traditional methods. Inivata’s proprietary platform TAm-Seq provides the ability to conduct next-generation sequence analysis of sizable genomic regions including entire genes or exons. Its gene panel includes a profile of 34 different cancer-related genes.
- Feb 2021Series C$35M
- May 2020Series C$49.5M
- Aug 2018Series B$52.8M
- Jan 2017Grant (prize money)—
#8
Series B · Cambridge, England · founded 2016 · 42 employees$82.8Mraised▾
Developer of live bacterial therapeutics and biomarkers for multiple diseases. The company identifies gut bacteria linked to phenotype with unprecedented precision to discover and develop live bacterial therapeutics and biomarkers for Inflammatory bowel disease, Immuno-oncology, and Gut Epithelial Barrier Repair.
- Mar 2022Series B$67M
- May 2018Series A$5.4M
- Dec 2016Series A$10.4M
#9
Acquired · Cambridge, England · founded 2013 · 79 employees$81.9Mraised▾
Developer of software for clinical genomic interpretation and variant analysis. This platform processes raw sequencing data to identify genetic variants associated with rare diseases, oncology, and infectious conditions. It provides tools for variant ranking and clinical reporting to support diagnostic workflows. The system integrates phenotype data to assist in the assessment of genomic information for medical decision-making.
- Jun 2021Grant (prize money)$2.8M
- Nov 2020Series C$50M
- Apr 2019Series B$17.1M
- Apr 2017Series B—
#10
Series A · Cambridge, England · founded 2020 · 4 employees$15Mraised▾
Developer of biopharmaceutical products & cell therapies by using genome sequencing data. It has developed sequencing tools that help in the development of medicines, including cell and gene therapies for the treatment of cancer, immunological health & other diseases. It develops INDUCE-seq technology for measuring DNA breaks throughout the genome & also determines the mechanism of DSB repair that facilitates the development of therapeutic genome editing.
- Sep 2023Series A$15M
- Jan 2022Seed—
- Feb 2021Seed—
#11
Series C · Cambridge, England · founded 2010 · 29 employees$56.7Mraised▾
Developer of single-cell analysis systems designed for single-cell dispensing and cell line and therapy development. The company's cell analysis systems assist in the discovery of new cell strains and molecules for use in single-cell analysis and characterization, helping life science companies in biologics discovery and accelerating biopharmaceutical discovery.
#12
Acquired · Cambridge, England · founded 1997 · 8185 employees$53.8Mraised▾
Developer of oncology therapies based on the inhibition of DNA repair. The technology was based on the science of DNA damage sensing, signaling, and repair and its potential in cancer treatment. It is developing small molecule drugs that selectively inhibit the DNA repair process in cancer cells thus facilitating their destruction and improving cancer management.
- Oct 2019Grant (prize money)$338K
- Jan 2019Grant (prize money)$325.2K
- Apr 2018Grant (prize money)$269.9K
- Jan 2018Grant (prize money)$111.5K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Genomics coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics in Cambridge is moving
A read on the academic research around Bioinformatics in Cambridge — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 240 papers.
- University of Cambridge194
- Cancer Research UK Cambridge Center27
- Cambridge University Hospitals NHS Foundation Trust24
- Cambridge School15
- Wellcome/MRC Cambridge Stem Cell Institute8
- Gene2→13
- Genome2→12
- Transcriptome2→11
- Disease1→5
- DNA sequencing1→5
- Genome6
- Computational biology4
- Missense mutation3
- In silico3
- Biomarker3
- Disease2→3
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.